Evidence map›Paper›PMID 39333731›Full record

ArticleScientific reports2024

Feature-based detection of breast cancer using convolutional neural network and feature engineering.

Hiba Allah Essa, Ebrahim Ismaiel, Mhd Firas Al Hinnawi

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Identification of Eye Diseases Through Deep Learning.Diagnostics (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hiba Allah EssaDepartment of Biomedical Engineering, Faculty of Electrical and Mechanical Engineering, Damascus University, Damascus, Syria. hiba.essa@damascusuniversity.edu.sy.
Ebrahim IsmaielFaculty of Biomedical Engineering, Al-Andalus University for Medical Sciences, Tartous, Syria. ei04@au.edu.sy.
Mhd Firas Al HinnawiDepartment of Biomedical Engineering, Faculty of Electrical and Mechanical Engineering, Damascus University, Damascus, Syria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) is a prominent cause of female mortality on a global scale. Recently, there has been growing interest in utilizing blood and tissue-based biomarkers to detect and diagnose BC, as this method offers a non-invasive approach. To improve the classification and prediction of BC using large biomarker datasets, several machine-learning techniques have been proposed. In this paper, we present a multi-stage approach that consists of computing new features and then sorting them into an input image for the ResNet50 neural network. The method involves transforming the original values into normalized values based on their membership in the Gaussian distribution of healthy and BC samples of each feature. To test the effectiveness of our proposed approach, we employed the Coimbra and Wisconsin datasets. The results demonstrate efficient performance improvement, with an accuracy of 100% and 100% using the Coimbra and Wisconsin datasets, respectively. Furthermore, the comparison with existing literature validates the reliability and effectiveness of our methodology, where the normalized value can reduce the misclassified samples of ML techniques because of its generality.

Indexed as

Breast NeoplasmsConvolutional Neural NetworksMachine LearningBiomarkersComputer SimulationData AnalysisData DisplayDatasets as TopicFemaleHumansBiomarkersBiomarkersBreast cancerConvolutional neural networksFeature engineeringGaussian distribution

Identifiers

PMID39333731
PMCPMC11436936

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.